Celéri Health and Corner Loc™ Announce Technology Collaboration for Study Data Gathering and Management
August 2023 –
PRESS RELEASE – August 17, 2023, Conshohocken, PA – Celéri Health is pleased to announce its collaboration with CornerLoc™ and its pending multi-center SPARTAN Study. Celéri Health will leverage its platform product, PainExplorer™ powered by SMART-TRIAL, for the data gathering and management in support of the Study. The SPARTAN Study is a multicenter, prospective, post-market surveillance study on the TransLoc 3D Sacroiliac Joint Fusion System including two treatment arms: 1) Lateral-Oblique TransLoc 3D Screw(s), 2) Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid). Data from this post-market study will be used to support knowledge of clinical efficacy and improvement with the use of TransLoc 3D Sacroiliac Joint Fusion System.. See Study information here: https://classic.clinicaltrials.gov/ct2/show/NCT05916092
PainIntel ROI Calculator
MedTech Strategist. May 2023 Digital Issue, Celéri Health Creates Foundation for Precision Pain Management
PainIntel ROI Calculator
PainIntel ROI Calculator
Celéri Health Creates Foundation for Precision Pain Management
May 2023 – MedTech Strategist – Digital Issue
Pain is individual, yet the field lacks biomarkers by which clinicians can tailor therapies to their patients. To enable more effective treatments, Celéri Health brings real-world data and an AI-enabled platform to clinicians and therapy developers to help them address the extreme heterogeneity of pain patients.
Celéri Health Announces First Of Its Kind PainRWD™ Science Cloud for Rapid Pain Data Collaboration
FOR IMMEDIATE RELEASE
Conshohocken, PA, August 22, 2022 – Celéri Health, LLC (“Celéri”),
Celéri Health, LLC (“Celéri”), the leading provider of pain-centric technology, has announced the offering of their database for pain researcher and stakeholder collaboration – called the PainRWD™ Science Cloud. As the world’s only pain data cloud, it offers Celéri clients and its collaborators a revolutionary way to come together and leverage live real-world data for population health, custom data registries, patient population aggregation, cohort generation by disease, and correlative modeling.
The launch of the PainRWD™ Science Cloud reflects the ongoing consensus that in order to improve the research and management of pain, a greater understanding is needed on the deep diversity of patients with pain. Historical epidemiological and clinical research can impose constraints that prevent modern stakeholders from visualizing the holistic view of a patient on a pain journey across their social presentation, demographics, severity, interventions, responsiveness and outcomes. The PainRWD™ Science Cloud offers a speedy and unique visualization to on-the-ground providers of pain care who may also be investigating with their own cohort or participating with other stakeholders in uncovering correlations between pain endpoints. It also allows for ease of use in looking at curated slices of pain data in co-existing conditions like diabetes, cancer, arthritis and others – which Celéri calls its Disease Communities.
The value of real-world data is that it can be used in real-time decision making for live patient care decisions, for custom population-based utilization review, risk management, value-based care modeling, process improvement, pre-authorization support and for bespoke research. This includes the marriage of subjective and objective data, risk stratification, agile incorporation of wearable sharing, and social determinants data. A live practice example includes the stigma surrounding the opioid crisis and the pain practitioner’s ongoing need to assess patients for risks around opioids. Opioid side effects, risk of misuse, and ongoing fatality rates muddy the waters around authorization and medical necessity. Live RWD for risk identification, likelihood of pharmaceutical response and social profile consideration is a novel solution.
“We have been operating quietly for some time and now we are positioned to launch into the broader market. Our participants to date are using RWD for risk mitigation, contract negotiation and most importantly therapeutic innovation. The response has been gratifying.” said President and CEO, Sean McCrossen. “We have a responsibility to enhance the lives of patients coping with pain and we are going to continue to innovate to meet our commitment.”
“We have a responsibility to enhance the lives of patients coping with pain and we are going to continue to innovate to meet our commitment.”
Celéri Health Announces Partnership with the University of Wisconsin–Madison to Incorporate Area Deprivation Index Data into Pain Management Services
FOR IMMEDIATE RELEASE
Conshohocken, PA, April 27, 2022 – Celéri Health, LLC (“Celéri”), Celéri Health is pleased to announce its partnership with the University of Wisconsin–Madison Center for Health Disparities Research, through which their Neighborhood Atlas® Area Deprivation Index (ADI) will be incorporated into Celéri’s comprehensive pain data services.
The ADI is a validated measure that incorporates 17 factors of social determinants of health (SDOH), such as income, education, employment, and housing quality, in order to rank neighborhood levels of disadvantage. Previous research has found that living in a disadvantaged neighborhood is associated with many health-related factors including limited access to nutritious food, more safety concerns and greater risk of toxic exposures, such as pollution. Individuals who live in such neighborhoods are more apt to develop certain diseases and to die earlier from those diseases. By considering a patient’s level of neighborhood disadvantage, providers may choose to tailor patient interventions that can improve health care delivery and patient outcomes. Strengths of this approach include a consistent standardized measurement and consideration of social and environmental factors that impact health. The U.S. Centers for Medicare and Medicaid Services currently uses the ADI to make adjustments for the Accountable Care Organization Realizing Equity Access and Community Health model. For more information visit https://www.neighborhoodatlas.medicine.wisc.edu/.
“It has been proven that pain severity/interference correlates positively with ADI” says Jason Pope, MD, one of the founders of Celéri Health. “Pain providers that have likely socioeconomic conditions of their patient front-and-center with other patient-reported outcomes like PROMIS-29 and Patient Global Impression of Change, for example – are better armed to provide a patient with a care pathway that meets their holistic needs.” Further, the CEO of Celéri Health, Sean McCrossen says, “We know that a patient’s pain story is influenced by a multitude of factors. Chronic pain is influenced by genetics, early life experiences, mood and psychological state, coexisting medical conditions, and environments.2 To that end, Celéri wants to work with its vast community of pain providers around gathering and sharing data representing as many of those co-existing environments as we can possibly bring to them.”
The Area Deprivation Index (ADI) is available to the clients of Celéri’s PainIntel™ as a correlative to their patient reported outcome measures and within the platform’s Pain Command Center for population health considerations.
“Celéri wants to work with its vast community of pain providers around gathering and sharing data representing as many of those co-existing environments as we can possibly bring to them.”
Interaxon Partners with Celéri Health to Validate Chronic Pain Intervention
Article originally published on Cision.
With the support of pain experts and industry leaders, Interaxon explores the therapeutic efficacy of its Muse® mEEG Biofeedback and new Transforming Pain eCourse for pain management
TORONTO, July 20, 2021 /PRNewswire/ — Interaxon, along with Celéri Health and pain expert Dr. Ronald D. Siegel, is testing a therapeutic intervention to help people better manage their chronic and acute pain. With the prevalence of pain and its multidimensional repercussions, this non-opioid alternative consisting of mindfulness tools, EEG biofeedback and psychoeducation, could offer an accessible and safer option to alleviate both patients’ symptoms and economic burden.
A recent study uncovered that over 50 million adults experience chronic pain in the US alone. According to the National Institute of Health on Drug Abuse, 21 to 29% of patients who are prescribed opioids for their pain end up misusing them, with 8 to 12% developing an opioid use disorder. With more than 70% of overdose deaths being opioid-involved, Congress has recently put forth the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act—legislation to increase access to non-opioid pain management alternatives. Interaxon and Celéri Health, a leader in chronic pain care data and data analytics, have launched a study on the effectiveness of an affordable, drug-free digital intervention that pain patients can easily access and complete from the comfort of home.
“In collaboration with our partners at Celéri Health and with Dr. Ronald Siegel, Interaxon has developed a sophisticated system that can be used to treat chronic pain,” says Dr. Walter Greenleaf, Interaxon’s Chief Science Officer. “Our system combines next-generation wearable sensor technology with a sophisticated pain-reduction therapeutic program. Our mobile app-based system is affordable and practical, opening up the possibility of dramatically improving the health and wellbeing of those who are burdened by chronic pain.”
Over a 7-week period, the pain management of fifty study participants suffering from chronic pain will be tested as they undergo programming including the Transforming Pain eCourse and biofeedback meditation training, both by Muse®, Interaxon’s consumer product brand. Celéri Health co-founders Michael Fishman, MD, and Jason Pope, MD, will assess participants using a cold pressor test and patient reported outcomes measures, including the clinically-validated PROMIS-29 multidimensional pain scale to detect changes in pain, anxiety, depression, physical function, sleep and quality of life.
“Chronic pain is the least data-driven chronic condition in the world, and we at Celéri Health are changing this,” states Jon Brilliant, CEO of Celéri Heath. “We are thrilled to be partnering with Interaxon and using Muse® to bring objective data, along with our extensive patient reported outcomes data, to how we measure outcomes and make treatment decisions for people living with pain.”
The Transforming Pain eCourse, currently available on a Muse® iOS app, was created in partnership with Ronald D. Siegel, PsyD, a mindfulness practitioner, chronic pain expert and part-time Assistant Professor of Psychology, at Harvard Medical School. The 65 sessions led by Dr. Siegel explore pain education, behavioural therapy techniques and pain-oriented mindfulness tools designed to transform one’s perception and relationship with pain to improve quality of life.
“The course is designed to simultaneously address several aspects of chronic pain disorder,” explains Dr. Siegel. “It uses mindfulness practices to increase distress tolerance, gain perspective on pain-amplifying thoughts, and interrupt the natural tendency to amplify pain sensations through hypervigilance and accompanying muscle tension. It also includes a program of incremental rehabilitation to help participants re-engage in meaningful life activities.”
Throughout the study, each participant will also have access to a Muse® brain-sensing headband, a focused attention meditation tool. Using biofeedback technology, the Muse® headband and app will help participants identify in real-time when their mind is wandering towards thoughts about their pain and coach them back to a neutral stimulus.
“A cornerstone treatment of pain is self-management of mood, sleep, comfort, and function. Muse biofeedback combined with pain education is a key component to a multimodal treatment plan that engages the patient in their own care and builds healthy habits and coping skills,” adds Dr. Fishman. “As an interventional pain care expert, I take great care to emphasize the importance of self-management for all my patients. Through our biosignal research with Interaxon, I hope to be able to further understand the different pain phenotypes so as to inform treatment decisions to help our patients get better and stay better.”
The study is expected to demonstrate an improvement in the experience of pain, behavioural health issues, depression, anxiety and sleep. Once results are available later this year, Interaxon hopes to bring the Muse® Transforming Pain Course and Mind Meditation intervention to market as a valuable low-barrier alternative to prescription pain relievers. With one in five American adults living with pain, it’s important to consider the overarching costs on quality of life, medical expenditure, the economy, and the opioid crisis. With chronic pain’s damaging ramifications, Interaxon’s pain program has the potential of offering an effective, non-addictive strategy to pain management.
For interviews and more information, contact Talia Noya at press@choosemuse.com.
About the MUSE-PAIN Study:
This study is a prospective, open-label, non-randomized study to assess the use of the Muse-S meditation system in patients with chronic pain based on clinical follow-up data and exploratory cold pressor testing. Patients will be followed for seven weeks for main study endpoints and will continue to be followed for 12 months during a study extension period. The first patient was enrolled on July 19, 2021 at the Center for Interventional Pain and Spine in Lancaster, Pennsylvania by Dr. Michael Fishman. Please refer to www.clinicaltrials.gov (NCT04944459) for additional clinical trial details.
About Celéri Health:
The mission of Celéri Health is to make pain a data driven disease by treating every encounter like a clinical study visit and capture of real-world evidence and data streams (Patient-reported Outcomes, diagnoses, drug history, procedure registry, wearables, and physiologic data). Our Real World Outcomes® platform operationalizes the consensus expert recommendations and we are building the largest most comprehensive real world outcomes data set in pain, including procedure and device registries, medical history, physiological data, and pharmaceutical usage. You can learn more about Celéri Health at www.celerihealth.com.
About Interaxon Inc. (aka Muse®):
Our team of neuroscientists, meditation teachers, and engineers develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build rewarding meditation and sleep practices to lead healthier, happier, and more connected lives through human-centered technology. Our award-winning biofeedback devices provide EEG-powered meditation and sleep tracking to help users tap into calm with real-time audio feedback on their internal state through the Muse® companion app. Deepen your practice with our premium offering of guided meditations and courses led by expert instructors. We make the intangible, tangible. More information about Muse® is available at www.choosemuse.com.
Milestones we’re excited about:
- Sessions of meditation with Muse®: Over 175 million minutes to date and currently one of the largest brain data (EEG) collections in the world.
- Research institutions using Muse®: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.
- Meditating with Muse® works: A recent study at the Catholic University of Milan showed that four weeks with Muse® significantly reduced stress as well as potentially influenced beneficial neuroplastic changes in users’ brains, compared to controls. Original published papers from the Balconi Lab study can be found here and here.
Media Contact: Talia Noya | Muse, press@choosemuse.com
This Wilmington medtech company is innovating new ways to measure pain
This article originally posted by Technical.ly.
Celéri Health, a Wilmington-based medtech company, aims to revolutionize pain measurement by developing a platform that goes beyond the traditional zero-to-10 rating scale. Led by Dr. Michael Fishman and Dr. Jason Pope, Celéri Health’s Real World Outcomes Platform collects real-world evidence and offers assessments based on the biopsychosocial model. The platform is used by healthcare providers across 12 states, aiming to improve treatment effectiveness for chronic pain patients.
